The BioDay Registry
This website is intended for patients, BioDay registry participants and anyone interested in the study.
In 2017, the BioDay registry was launched. This is a registry for recording data on the use of new drugs in constitutional eczema in daily practice.
In the BioDay registry, we follow patients with atopic dermatitis and study the efficacy, safety and patient satisfaction of new drugs in daily practice. Patients from different parts of the Netherlands are followed for at least 5 years, which makes the BioDay registry unique. This makes it possible to answer a wide range of questions.
Good to know
True alternative
"At our National Eczema Centre of Expertise, we mainly see patients with more severe forms of the disease who need to be treated with immunosuppressive drugs such as cyclosporine and methotrexate. About half of these patients stop taking these drugs because of inadequate response or too many side effects. I am very pleased that we are getting more and more new treatment options for these patients, which often work better than the older drugs and have also been extensively tested in large trials."
Prof. Dr. Marjolein de Bruin-Weller
Dermatologist UMC Utrecht
Your voice matters
"At UMC Groningen we have expertise in the assessment and treatment of patients with constitutional eczema, hand eczema and contact eczema and the possible relationship with work. When it comes to choosing a treatment, we take into account what is important to the patient. We do this by taking a broad view of the effect of a treatment on related conditions, such as hand eczema and asthma. The collection of this data in BioDay also gives us an insight into the effect of new drugs on these diseases.
Dr. Marie-Louise Schuttelaar
Dermatologist UMC Groningen
